ReviewFrontiers in pharmacology2021
Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 46 citations in OpenAlex.
- AI-enabled language models (LMs) to large language models (LLMs) and multimodal large language models (MLLMs) in drug discovery and development.Journal of advanced research · 2025Review
- Mucosal implications of oral Jak3-targeted drugs in COVID patients.Molecular medicine (Cambridge, Mass.) · 2025Review
- Experience and side effects of COVID-19 vaccine uptake among university students: a cross-sectional survey study.Frontiers in public health · 2024Article
- Prescription patterns in an intensive care unit of COVID-19 patients in Bangladesh: A cross-sectional study.Health science reports · 2023Article
- The Role of Cyclodextrins in COVID-19 Therapy-A Literature Review.International journal of molecular sciences · 2023Review
- Drugs for COVID-19: An Update.Molecules (Basel, Switzerland) · 2022Review
- An Overview of Repurposed Drugs for Potential COVID-19 Treatment.Antibiotics (Basel, Switzerland) · 2022Review
- Molecular Bases of Serotonin Reuptake Inhibitor Antidepressant-Attributed Effects in COVID-19: A New Insight on the Role of Bradykinins.Journal of personalized medicine · 2022Review
- Hemolytic anemia in COVID-19.Annals of hematology · 2022Review
- Comparative genomics, evolutionary epidemiology, and RBD-hACE2 receptor binding pattern in B.1.1.7 (Alpha) and B.1.617.2 (Delta) related to their pandemic response in UK and India.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2022Article
- Safety and efficacy of favipiravir for the management of COVID-19 patients: A preliminary randomized control trial.Clinical infection in practice · 2022Article
- Article
- Therapeutic approaches and vaccination in fighting COVID-19 infections: A review.Gene reports · 2022Review
- A review on drug repurposing in COVID-19: from antiviral drugs to herbal alternatives.Journal, genetic engineering & biotechnology · 2022Review
- Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm.Life (Basel, Switzerland) · 2022Review
- Therapeutic effects of eperisone on pulmonary fibrosis via preferential suppression of fibroblast activity.Cell death discovery · 2022Article
- Baseline uric acid levels and steady-state favipiravir concentrations are associated with occurrence of hyperuricemia among COVID-19 patients.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Article
- Harnessing autophagy to fight SARS-CoV-2: An update in view of recent drug development efforts.Journal of cellular biochemistry · 2022Review
- The Time Has Come to Understand the Mechanisms by Which Comorbidities Contribute to COVID-19 Severity.Journal of personalized medicine · 2022Article
- Prospective Medicinal Plants and Their Phytochemicals Shielding Autoimmune and Cancer Patients Against the SARS-CoV-2 Pandemic: A Special Focus on Matcha.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19, transmitted by SARS-CoV-2, is one of the most serious pandemic situations in the history of mankind, and has already infected a huge population across the globe. This horrendously contagious viral outbreak was first identified in China and within a very short time it affected the world's health, transport, economic, and academic sectors. Despite the recent approval of a few anti-COVID-19 vaccines, their unavailability and insufficiency along with the lack of other potential therapeutic options are continuing to worsen the situation, with valuable lives continuing to be lost. In this situation, researchers across the globe are focusing on repurposing prospective drugs and prophylaxis such as favipiravir, remdesivir, chloroquine, hydroxychloroquine, ivermectin, lopinavir-ritonavir, azithromycin, doxycycline, ACEIs/ARBs, rivaroxaban, and protease inhibitors, which were preliminarily based on
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.